A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure
Braz. j. med. biol. res
;
53(11): e9728, 2020. tab, graf
Article
in English
| LILACS, ColecionaSUS
| ID: biblio-1132496
ABSTRACT
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Hepatitis B virus
/
Granulocyte Colony-Stimulating Factor
/
Hepatitis B
Type of study:
Controlled clinical trial
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. med. biol. res
Year:
2020
Type:
Article
Institution/Affiliation country:
Fifth Medical Center of Chinese PLA General Hospital/CN
/
Medical School of Chinese PLA/CN
/
Peking University International Hospital/CN
Similar
MEDLINE
...
LILACS
LIS